March 21, 2011
/PRNewswire/ -- Cellceutix Corporation (OTCQB: CTIX), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat severe medical conditions including drug-resistant cancers, today announced that it will be presenting a poster titled
"Kevetrin™, A Novel Small Molecule, Activates p53, Enhances Expression of p21, Induces Cell Cycle Arrest and Apoptosis in a Human Cancer Cell Line"
at the American Association for Cancer Research (AACR) 102nd Annual Meeting 2011 to be held
April 2-6, 2011
Samuel J. Danishefsky, Ph.D,
a member of the Cellceutix Scientific Advisory Board, commented, "I continue to be impressed with the data on Kevetrin™. The latest data, to be presented in poster form at the AACR, could prove to be quite significant as a breakthrough in p53 activation and has the potential to help reshape the landscape of therapies available for cancer treatment. I look forward to Cellceutix's transition from pre-clinical to clinical phases with the commencement of Phase I trials and remain excited about the future of Kevetrin™ based on the research conducted to this point."
Dr. Danishefsky was the recipient of the First Annual AACR-CICR Award for Outstanding Achievement in Chemistry in Cancer Research. The award honors novel and significant chemistry research which has led to important contributions to the field of cancer research. Dr. Danishefsky is the Kettering Chair and Director of the Laboratory for Bioorganic Chemistry at the world-renowned Memorial Sloan-Kettering Cancer Center in
New York City
and a professor of Chemistry at
Cellceutix Chief Scientific Officer, Dr.
, stated, "The positive feedback from Dr. Danishefsky is extremely encouraging as he is regarded among the world's leading chemists. We are privileged to have a man of his caliber on our Scientific Advisory Board." Dr. Menon continued, "We are honored to be selected by the AACR to present a poster on Kevetrin™. We are receiving regular correspondence regarding Kevetrin™ since the p53 breakthrough was announced a few weeks ago and this gives us an opportunity to communicate the data on a personal level with many of the premier oncology researchers from the world's leading companies."
Cellceutix is currently finalizing and reviewing all Investigational New Drug (IND) documentation for submission to the United States Food and Drug Administration, in
Cellceutix Corporation is presently a preclinical drug developer. Cellceutix owns the rights to eight drug compounds, including Kevetrin, which it is developing as a treatment for cancers; KM-133, for the treatment of psoriasis; and KM-391, for the treatment of autism. More information is available on the Cellceutix web site at
Kevetrin, KM133, and KM-391 have not been studied in humans at this time. The Company's positive results in animal studies do not necessarily guarantee success in humans, though they may form the basis for beginning Phase 1 trials.